search
Back to results

"Steroids and Azathioprine Versus Steroids Alone in IgAN"

Primary Purpose

IGA Nephropathy

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
steroids plus azathioprine
steroids
Sponsored by
A. Manzoni Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for IGA Nephropathy focused on measuring IgA nephropathy, steroids, azathioprine, chronic kidney disease progression, proteinuria

Eligibility Criteria

16 Years - 70 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • biopsy proven IgA nephropathy
  • creatinine ≤ 2.0 mg/dl for at least three months
  • proteinuria ≥ 1.0 g/day for at least three months

Exclusion Criteria:

  • treatment with steroids or cytotoxic drugs during the previous three years
  • contraindications to steroids or azathioprine
  • Henoch-Schöenlein purpura
  • diabetes mellitus
  • severe hypertension (diastolic blood pressure > 120 mmHg)
  • lupus erythematosus systemicus
  • malignancies
  • active peptic-ulcer disease
  • pregnancy
  • viral hepatitis or other infections

Sites / Locations

  • Hospital "Bolognini"
  • Hospital of Montichiari
  • Hospital "S.Anna"
  • Hospital "Istituti Ospitalieri"
  • Hospital "S.Marta e S.Venera",
  • Hospital "S.Vincenzo"
  • Department of Nephrology and Dialysis, A. Manzoni Hospital
  • Hospital "Maggiore"
  • Hospital "Uboldo"
  • Hospital of Desio
  • Hospital "Maggiore" IRCCS
  • Hospital "A.Segni"
  • Hospital "Spedali Civili"
  • "G. Brotzu" Hospital
  • Hospital "Cannizzaro"
  • Hospital "Careggi"
  • Hospital of University
  • Hospital "C. Poma"
  • Hospital "S. Francesco"
  • Hospital "V. Cervello"
  • University Hospital
  • Fondazione Maugeri" IRCCS
  • CNR-IBIM
  • Hospital "S. Maria Nuova"
  • Hospital of Sondrio
  • CMID
  • Hospital "Belcolle"
  • Inselspital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

Six month steroid course plus azathioprine

six month steroid course

Outcomes

Primary Outcome Measures

progression of renal disease, estimated by the time to 50% increase in plasma creatinine from baseline.

Secondary Outcome Measures

evolution of proteinuria over time
safety

Full Information

First Posted
September 18, 2008
Last Updated
September 18, 2008
Sponsor
A. Manzoni Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT00755859
Brief Title
"Steroids and Azathioprine Versus Steroids Alone in IgAN"
Official Title
Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2008
Overall Recruitment Status
Completed
Study Start Date
May 1998 (undefined)
Primary Completion Date
December 2004 (Actual)
Study Completion Date
September 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
A. Manzoni Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In a previous trial the investigators found that the effect of steroids in IgA nephropathy diminish over time. The difference in renal survival is striking up till the third year, but then remains constant. A six-month course of steroid therapy may be not enough to ensure a stable remission. The investigators hypothesized that a more aggressive treatment may obtain long-term better results. The investigators conducted a randomised controlled trial to assess the utility of low-dose azathioprine added to steroids in adult IgAN patients.
Detailed Description
In 1999, we published a multicenter, randomized, controlled trial, which compared a 6-month steroid course with supportive therapy in 86 patients with IgAN. After 5 years of follow-up, the risk of a 50% increase in plasma creatinine from baseline was significantly lower in the treated patients; proteinuria also decreased. However, the effect of steroids seemed to diminish over time. The difference in renal survival was particularly striking up till the third year, but then remained constant. We hypothesised that a six-month course of steroid therapy is not enough to ensure a stable remission, and a more aggressive treatment may be required to obtain long-term better results. At this regard, some studies of combined treatment with corticosteroids and azathioprine found that treatment was effective in preserving renal function and in reducing proteinuria. However, these studies did not clarify whether azathioprine added further benefit to steroids in the long term. We conducted a randomised controlled trial to assess the utility of low-dose azathioprine added to steroids in adult IgAN patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
IGA Nephropathy
Keywords
IgA nephropathy, steroids, azathioprine, chronic kidney disease progression, proteinuria

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
206 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Six month steroid course plus azathioprine
Arm Title
2
Arm Type
Active Comparator
Arm Description
six month steroid course
Intervention Type
Drug
Intervention Name(s)
steroids plus azathioprine
Other Intervention Name(s)
solumedrol, deltacortene, azatioprina
Intervention Description
methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
Intervention Type
Drug
Intervention Name(s)
steroids
Other Intervention Name(s)
solumedrol, deltacortene
Intervention Description
methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
Primary Outcome Measure Information:
Title
progression of renal disease, estimated by the time to 50% increase in plasma creatinine from baseline.
Time Frame
Every month for the first six months, then six months
Secondary Outcome Measure Information:
Title
evolution of proteinuria over time
Time Frame
every months for the first six months and then every six months
Title
safety
Time Frame
every months for the first six months and then every six months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: biopsy proven IgA nephropathy creatinine ≤ 2.0 mg/dl for at least three months proteinuria ≥ 1.0 g/day for at least three months Exclusion Criteria: treatment with steroids or cytotoxic drugs during the previous three years contraindications to steroids or azathioprine Henoch-Schöenlein purpura diabetes mellitus severe hypertension (diastolic blood pressure > 120 mmHg) lupus erythematosus systemicus malignancies active peptic-ulcer disease pregnancy viral hepatitis or other infections
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Claudio Pozzi, MD
Organizational Affiliation
A Manzoni Hospital, Lecco, Italy
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Francesco Locatelli, MD
Organizational Affiliation
A Manzoni Hospital, Lecco, Italy
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Simeone Andrulli, MD
Organizational Affiliation
A Manzoni Hospital, Lecco, Italy
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Antonello Pani, MD
Organizational Affiliation
Hospital "G. Brotzu", Cagliari, Italy
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Paolo Altieri, MD
Organizational Affiliation
Hospital "G. Brotzu", Cagliari, Italy
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Gian B Fogazzi, MD
Organizational Affiliation
Hospital "Maggiore" IRCCS, Milan, Italy
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Claudio Ponticelli, MD
Organizational Affiliation
Hospital "Maggiore" IRCCS, Milan, Italy
Official's Role
Study Director
Facility Information:
Facility Name
Hospital "Bolognini"
City
Seriate
State/Province
BG
Country
Italy
Facility Name
Hospital of Montichiari
City
Montichiari
State/Province
Brescia
Country
Italy
Facility Name
Hospital "S.Anna"
City
Como
State/Province
CO
ZIP/Postal Code
22100
Country
Italy
Facility Name
Hospital "Istituti Ospitalieri"
City
Cremona
State/Province
CR
Country
Italy
Facility Name
Hospital "S.Marta e S.Venera",
City
Acireale
State/Province
CT
Country
Italy
Facility Name
Hospital "S.Vincenzo"
City
Taormina
State/Province
CT
Country
Italy
Facility Name
Department of Nephrology and Dialysis, A. Manzoni Hospital
City
Lecco
State/Province
LC
ZIP/Postal Code
23900
Country
Italy
Facility Name
Hospital "Maggiore"
City
Lodi
State/Province
LO
Country
Italy
Facility Name
Hospital "Uboldo"
City
Cernusco sul Naviglio
State/Province
MI
Country
Italy
Facility Name
Hospital of Desio
City
Desio
State/Province
MI
Country
Italy
Facility Name
Hospital "Maggiore" IRCCS
City
Milano
State/Province
MI
Country
Italy
Facility Name
Hospital "A.Segni"
City
Ozieri
State/Province
Nuoro
Country
Italy
Facility Name
Hospital "Spedali Civili"
City
Brescia
Country
Italy
Facility Name
"G. Brotzu" Hospital
City
Cagliari
Country
Italy
Facility Name
Hospital "Cannizzaro"
City
Catania
Country
Italy
Facility Name
Hospital "Careggi"
City
Firenze
Country
Italy
Facility Name
Hospital of University
City
Foggia
Country
Italy
Facility Name
Hospital "C. Poma"
City
Mantova
Country
Italy
Facility Name
Hospital "S. Francesco"
City
Nuoro
Country
Italy
Facility Name
Hospital "V. Cervello"
City
Palermo
Country
Italy
Facility Name
University Hospital
City
Parma
Country
Italy
Facility Name
Fondazione Maugeri" IRCCS
City
Pavia
Country
Italy
Facility Name
CNR-IBIM
City
Reggio Calabria
Country
Italy
Facility Name
Hospital "S. Maria Nuova"
City
Reggio Emilia
Country
Italy
Facility Name
Hospital of Sondrio
City
Sondrio
Country
Italy
Facility Name
CMID
City
Torino
Country
Italy
Facility Name
Hospital "Belcolle"
City
Viterbo
Country
Italy
Facility Name
Inselspital
City
Bern
Country
Switzerland

12. IPD Sharing Statement

Citations:
PubMed Identifier
10630693
Citation
Locatelli F, Pozzi C, Del Vecchio L, Andrulli S, Pani A, Fogazzi G, Altieri P, Ponticelli C. Combined treatment with steroids and azathioprine in IgA nephropathy: design of a prospective randomised multicentre trial. J Nephrol. 1999 Sep-Oct;12(5):308-11.
Results Reference
background

Learn more about this trial

"Steroids and Azathioprine Versus Steroids Alone in IgAN"

We'll reach out to this number within 24 hrs